Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Korro Bio, Inc. stock logo
KRRO
Korro Bio
$13.42
-0.9%
$14.65
$10.29
$98.00
$125.98M2.45110,704 shs20,611 shs
LifeVantage Co. stock logo
LFVN
LifeVantage
$12.71
+2.3%
$12.84
$5.22
$27.38
$159.99M0.43145,444 shs20,729 shs
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$3.47
+3.4%
$3.18
$2.22
$4.13
$171.97M1.29439,029 shs63,582 shs
Alterity Therapeutics Limited stock logo
PRAN
Alterity Therapeutics
$4.40
-4.1%
$1.41
$1.09
$2.91
$39.16M1.05130,956 shs22,706 shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Korro Bio, Inc. stock logo
KRRO
Korro Bio
0.00%-7.20%-10.39%-45.97%-67.45%
LifeVantage Co. stock logo
LFVN
LifeVantage
0.00%-0.72%-7.17%-27.05%+80.14%
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
0.00%-9.95%-1.18%+3.40%+7.72%
Alterity Therapeutics Limited stock logo
PRAN
Alterity Therapeutics
0.00%-6.98%+16.09%+11.68%+136.56%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Korro Bio, Inc. stock logo
KRRO
Korro Bio
3.5375 of 5 stars
4.63.00.00.04.10.00.6
LifeVantage Co. stock logo
LFVN
LifeVantage
3.9875 of 5 stars
3.50.01.72.72.91.71.3
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
3.9856 of 5 stars
3.52.00.00.02.43.33.1
Alterity Therapeutics Limited stock logo
PRAN
Alterity Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Korro Bio, Inc. stock logo
KRRO
Korro Bio
3.29
Buy$102.43663.54% Upside
LifeVantage Co. stock logo
LFVN
LifeVantage
3.00
Buy$30.50139.97% Upside
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
3.00
Buy$7.00102.02% Upside
Alterity Therapeutics Limited stock logo
PRAN
Alterity Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest PRAN, KRRO, PBYI, and LFVN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/13/2025
Korro Bio, Inc. stock logo
KRRO
Korro Bio
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00 ➝ $25.00
5/13/2025
Korro Bio, Inc. stock logo
KRRO
Korro Bio
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$155.00 ➝ $90.00
5/8/2025
Korro Bio, Inc. stock logo
KRRO
Korro Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$115.00 ➝ $100.00
4/29/2025
Korro Bio, Inc. stock logo
KRRO
Korro Bio
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/28/2025
Korro Bio, Inc. stock logo
KRRO
Korro Bio
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$74.00
4/16/2025
Korro Bio, Inc. stock logo
KRRO
Korro Bio
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$25.00
3/20/2025
Korro Bio, Inc. stock logo
KRRO
Korro Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$115.00 ➝ $115.00
3/19/2025
Korro Bio, Inc. stock logo
KRRO
Korro Bio
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$105.00 ➝ $95.00
(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Korro Bio, Inc. stock logo
KRRO
Korro Bio
$4.82M26.13N/AN/A$21.19 per share0.63
LifeVantage Co. stock logo
LFVN
LifeVantage
$222.35M0.72$0.67 per share19.03$2.38 per share5.34
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$232.71M0.74$0.83 per share4.19$1.12 per share3.09
Alterity Therapeutics Limited stock logo
PRAN
Alterity Therapeutics
$150K261.07N/AN/A$1.40 per share3.14
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Korro Bio, Inc. stock logo
KRRO
Korro Bio
-$81.17M-$9.44N/AN/AN/AN/A-50.25%-38.48%8/12/2025 (Estimated)
LifeVantage Co. stock logo
LFVN
LifeVantage
$2.94M$0.6922.70N/A3.46%34.29%15.04%8/27/2025 (Estimated)
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$21.59M$0.777.229.12N/A9.56%41.60%10.71%7/30/2025 (Estimated)
Alterity Therapeutics Limited stock logo
PRAN
Alterity Therapeutics
-$6.40M-$0.70N/AN/AN/AN/AN/AN/A

Latest PRAN, KRRO, PBYI, and LFVN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2025Q1 2025
Korro Bio, Inc. stock logo
KRRO
Korro Bio
-$2.60-$2.49+$0.11-$2.49$0.13 million$2.55 million
5/6/2025Q3 2025
LifeVantage Co. stock logo
LFVN
LifeVantage
$0.16$0.26+$0.10$0.26$60.99 million$58.44 million
3/18/2025Q4 2024
Korro Bio, Inc. stock logo
KRRO
Korro Bio
-$2.33-$2.26+$0.07-$2.26N/A$2.27 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Korro Bio, Inc. stock logo
KRRO
Korro Bio
N/AN/AN/AN/AN/A
LifeVantage Co. stock logo
LFVN
LifeVantage
$0.181.42%N/A26.09%3 Years
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
N/AN/AN/AN/AN/A
Alterity Therapeutics Limited stock logo
PRAN
Alterity Therapeutics
N/AN/AN/AN/AN/A

Latest PRAN, KRRO, PBYI, and LFVN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2025
LifeVantage Co. stock logo
LFVN
LifeVantage
quarterly$0.04501.5%5/30/20255/30/20256/13/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Korro Bio, Inc. stock logo
KRRO
Korro Bio
N/A
11.23
11.23
LifeVantage Co. stock logo
LFVN
LifeVantage
N/A
1.66
1.03
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
0.46
1.42
1.40
Alterity Therapeutics Limited stock logo
PRAN
Alterity Therapeutics
N/A
4.37
N/A

Institutional Ownership

CompanyInstitutional Ownership
Korro Bio, Inc. stock logo
KRRO
Korro Bio
13.18%
LifeVantage Co. stock logo
LFVN
LifeVantage
35.32%
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
61.29%
Alterity Therapeutics Limited stock logo
PRAN
Alterity Therapeutics
3.63%

Insider Ownership

CompanyInsider Ownership
Korro Bio, Inc. stock logo
KRRO
Korro Bio
4.60%
LifeVantage Co. stock logo
LFVN
LifeVantage
20.65%
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
23.30%
Alterity Therapeutics Limited stock logo
PRAN
Alterity Therapeutics
38.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Korro Bio, Inc. stock logo
KRRO
Korro Bio
709.39 million8.86 millionNo Data
LifeVantage Co. stock logo
LFVN
LifeVantage
26012.59 million9.96 millionOptionable
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
20049.63 million37.45 millionOptionable
Alterity Therapeutics Limited stock logo
PRAN
Alterity Therapeutics
148.90 millionN/ANot Optionable

Recent News About These Companies

Alterity Therapeutics completes placement
Alterity Therapeutics announces regulatory notice
Alterity Therapeutics Ltd PBN
Alterity Therapeutics to List New Securities on ASX
Alterity Therapeutics raises A$40M in placement
Alterity Therapeutics price target raised to $12 from $8 at Maxim

New MarketBeat Followers Over Time

Media Sentiment Over Time

Korro Bio stock logo

Korro Bio NASDAQ:KRRO

$13.42 -0.13 (-0.92%)
As of 01:12 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

LifeVantage stock logo

LifeVantage NASDAQ:LFVN

$12.71 +0.28 (+2.25%)
As of 01:12 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

Puma Biotechnology stock logo

Puma Biotechnology NASDAQ:PBYI

$3.46 +0.12 (+3.43%)
As of 01:12 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Alterity Therapeutics stock logo

Alterity Therapeutics NASDAQ:PRAN

Alterity Therapeutics Ltd. engages in the development of therapeutic drugs designed to treat the underlying causes of degeneration of the brain as the aging process progresses. It focuses on Parkinson's movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.